Patients with allogeneic hematopoietic cell transplants are needed for a study to research an investigative cellular therapy to prevent life threatening viral infections compared to a placebo

UVA Tracking #
Principal Investigator
Indumathy Varadarajan
Sara Casana Granell
Contact Phone
Official Trial Title
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Viralym-M Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allo
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have allogeneic hematopoietic cell transplants. The purpose of this study to evaluate an investigational drug (Viralym-M) versus a placebo in patients with allogeneic hematopoietic cell transplants and may develop viral infections. The effects of the investigational drug will be evaluated for this study.

Participation includes an optional pre-screening visit, a 6 week screening period, about 4 months of treatment, with a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. Study specific test will be provided at no cost to you.

Additional information can be found here:

Reimbursement: You will receive up to $175 for hotel stays per night.


You will receive $50 per study visit if you live under 100 miles away. You will be paid the IRS Rate per mile if you live over 100 miles away.